Table 1 Characteristics and results for standard-dose cohort (left) and intermediate-dose cohort (right)

Age (years)

23

58

[46.5 - 63.5]

35

53

[45.5 - 67]

p = 0.874

Weight (kg)

23

90

[79 - 96.5]

35

86

[76.5 - 98]

p = 0.427

Body Mass Index

23

30.3

[25.8 - 32.0]

35

29

[24.8 - 31.3]

p = 0.276

APACHE II Score

20

12.5

[11.8 - 15.3]

32

12.5

[10 - 16.3]

p = 0.699

Critical Care admission (days)

23

19

[12 - 22]

34

15

[9.3 - 21]

p = 0.353

P/F Ratio (kPa)

23

19.4

[15.3 - 26.9]

35

18.5

[15.4 - 25.3]

p = 0.674

PEEP (cmH2O)

22

11

[8.5 - 12.8]

34

10

[7.5 - 10]

p = 0.033

Noradrenaline (mcg/kg/min)

23

0

[0 - 0.01]

35

0

[0 - 0]

p = 0.053

Creatinine (micromol/L)

23

74

[57 - 99]

35

64

[53 - 81]

p = 0.097

Estimated fluid balance (ml)

23

2800

[1650 - 6250]

33

700

[0 - 1900]

p < 0.001

First Anti-Factor Xa level (IU/ml)

23

0.13

[0.06 - 0.18]

35

0.26

[0.21 - 0.33]

p < 0.001

Starting daily dose enoxaparin (mg)

23

40

[40 - 40]

35

80

[80 - 80]

p < 0.001

Dose by weight (mg/kg)

23

0.44

[0.42 - 0.51]

35

0.93

[0.82 - 1.04]

p < 0.001

Adjustment period (days)

16

2

[0 - 3]

34

0

[0 - 0.8]

p = 0.003